The global hyperlipidemia drugs market size reached USD 23.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 27.2 Billion by 2033, exhibiting a growth rate (CAGR) of 1.69% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 23.1 Billion |
Market Forecast in 2033
|
USD 27.2 Billion |
Market Growth Rate (2025-2033) | 1.69% |
Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.
The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on drug type and end user.
Breakup by Drug Type:
Breakup by End User:
Breakup by Region:
The report has also provided a comprehensive analysis of the competitive landscape in the global hyperlipidemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Drug Type, End User, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global hyperlipidemia drugs market was valued at USD 23.1 Billion in 2024.
We expect the global hyperlipidemia drugs market to exhibit a CAGR of 1.69% during 2025-2033.
The rising demand for hyperlipidemia drugs to treat high cholesterol levels caused by genetic factors, unhealthy lifestyles, and inadequate diet is primarily driving the global hyperlipidemia drugs market.
The sudden outbreak of the COVID-19 pandemic has led to the increasing demand for hyperlipidemia drugs to provide safety from continuing lipid-lowering medication to the patients suffering from the coronavirus infection.
Based on the drug type, the global hyperlipidemia drugs market has been segmented into statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and others. Currently, statins hold the majority of the total market share.
Based on the end user, the global hyperlipidemia drugs market can be divided into hospitals, clinics, and others. Among these, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where Europe currently dominates the global market.
Some of the major players in the global hyperlipidemia drugs market include Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc., and Sanofi S.A.